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Abstract
Background:  Neck dissection is an important surgical procedure for the management of
metastatic nodal disease in the neck. The gold standard of neck nodal management has been the
radical neck dissection. Any modification in the neck dissection is always compared with this
standard. Over the last few decades, in order to alleviate the morbidity of radical neck dissection,
several modifications and conservative procedures have been advocated. These procedures retain
certain lymphatic or non-lymphatic structures and have been shown not to compromise
oncological safety.
Methods: A literature search of the Medline was carried out for all articles on neck dissections.
The articles were systematically reviewed to analyze and trace the evolution of neck dissection.
These were then categorized to address the nomenclature, management of node positive and node
negative neck including those who had received chemoradiation.
Results: The present article discusses the neck nodal nomenclature, the radical neck dissection,
its modifications and migration to more conservative procedures and possible advances in the near
future.
Conclusion: Radical neck dissection is now replaced with modified radical neck dissections in
most situations. Attempts are being made to replace modified radical neck dissections with
selective neck dissections for early node positivity. Sentinel node biopsy is being studied to address
the issue of node negative neck. More conservative surgeries are likely to replace the 'radical'
surgeries of bygone era. This process is facilitated by earlier detection of the disease and better
understanding of cancer biology.
Background
Gasparo Aselli, in 1622, first described the lacteal vessels
indicating the presence of a lymphatic system. Paolo Mas-
cagni, in 1787, and Sappey, in 1875, published atlases on
lymphatics. Most of the later knowledge was derived from
autopsy or post-surgical studies on nodes. The standard
anatomical depictions of nodes and their drainage were
based on Rouviere's descriptions. Surgical removal of
nodes has paralleled the anatomical understanding. From
these in vitro autopsy or post surgical studies on lymph
drainage, we have progressed to in vivo sentinel node
evaluation.
In the early 1800s, complete removal of disease was con-
sidered impossible once cancer had spread to 'cervical
glands', although Warren in 1847 described an operation
for removal of metastatic neck nodes. Butlin advised
removal of nodes through a Köcher incision. A systematic
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operative procedure for removal of cervical lymphatics
and nodes, and the first description of radical neck dissec-
tion (RND) based on anatomical principles, was
described by George Crile Sr., in 1906 [1]. Hayes Martin
(the father of modern head and neck cancer surgery) and
his associates standardized the technique of RND [2].
Both of these surgeons followed Halsted's principles
which were popular at that time. The RND is still consid-
ered by some to be the 'gold standard' treatment for neck
nodes. However, modifications of the procedure are
accepted and are being performed with increasing fre-
quency. Research into breast cancer has contributed a
great deal to the understanding of cancer as a systemic dis-
ease in contrast to the earlier Halstedian principles that
cancer followed an anatomical step-wise progress. Suarez
proposed that muscles, vessels and nerves could be pre-
served without adversely affecting regional control and
described 'functional neck dissection' [3]. With increasing
knowledge of tumor biology, the next stage in the surgery
of metastatic neck disease was the promotion of the func-
tional neck dissection by Bocca [4]. A comparable recur-
rence rate compared with that of RND was also claimed
[5]. Later studies have shown that there is no compromise
on oncological effectiveness even though there is devia-
tion from the previous standard en bloc resection.
The regional lymphatics
Regional lymphatic drains from the scalp and skin of head
and neck region, the mucosa of the upper aero-digestive
tract, salivary glands, and the thyroid gland to specific
regional lymph nodal groups. In addition, tumor dissem-
ination via regional lymphatics to these lymph node
groups occurs in a predictable and sequential fashion.
Hence, specific regional lymph node groups should be
appropriately addressed in treatment planning for a given
primary tumor site. The anatomy of the nodal involve-
ment and the biology of the disease have to be considered
in planning treatment.
At this stage it is essential that we understand the division
of neck nodes into 'nodal groups' described as 'levels'
rather than 'anatomical regional groups'. This serves the
dual purpose of understanding the natural anatomical
spread of disease and the principles of various neck dissec-
tions. The nomenclature has been standardized for uni-
formity in documentation and cross-communication.
Retrospective studies have documented the patterns of
spread of cancers from various primary sites in the head
and neck area to cervical nodes [6]. The terminology for
categorizing the lymph node groups was originally
described at Memorial Sloan-Kettering Cancer Centre,
New York, and is widely accepted. It divides the hemi-
neck into five regions. A sixth region was added later [7].
The nodal levels are diagrammatically shown in figure 1
and a brief description of neck nodal levels [8] is
described in Table 1. The regional lymph node staging [9]
is described in Table 2. Thus, all regional nodes are not at
risk of metastases initially from any primary site in the
absence of grossly palpable nodes. For example, in oral
tumors, if neck is clinically negative, level IV and V nodes
are generally not at risk of harboring micro-metastases. A
similar situation applies to other organ and node metas-
tases. The first nodal basin varies for each site and is
described in the Table 3. Skip metastases in the absence of
first echelon nodes being involved are unusual. On the
other hand, when clinically palpable nodes are present,
comprehensive clearance of all regional nodal groups is
warranted (see also discussion under selective dissection
for node positive neck). Several well documented studies
have confirmed this to be the case [7].
The risk of nodal metastases is dependent on various fac-
tors related to the primary tumor. These include the site,
size (large or small), T stage, location of the primary
tumor (within an organ such as the vocal cord compared
with supraglottis) and histomorphology of the primary
tumor. The risk of metastases increases as one progresses
from the anterior to posterior part of the upper aero-diges-
tive tract; from lip (10%) progressing along the tongue
(25%), gum (30%), floor of mouth (40%), oropharynx
(55%) to hypopharynx (65%). Endophytic tumors,
poorly differentiated tumors, and tumors with a greater
thickness (tongue and floor of mouth) are more likely to
have metastases [10].
The goal of treatment of cervical nodal metastases is
regional control of disease. Micrometastases and minimal
gross metastases may be controlled by radiotherapy but
surgery remains the mainstay of treatment as it provides
comprehensive clearance of all grossly enlarged nodes
and offers accurate histological information regarding the
presence of micrometastases. While the indications for
comprehensive surgical clearance of regional nodes in
patients with clinically metastatic disease are obvious, the
indications for elective nodal dissection (END) in patients
with N0 neck status are more challenging and are dis-
cussed separately. The present discussion is aimed at
answering why, when, and how to treat neck nodes in
patients with primary squamous head and neck cancers?
Neck dissection nomenclature
The term "neck dissection" refers to a surgical procedure
in which the fibro-fatty soft tissue content of the neck is
excised to remove the lymph nodes that are contained
therein [11]. Over the years, a number of variations and
modifications of RND have been described. In addition,
different terminologies have been used to represent the
same surgery as well as different surgeries. The classifica-
tion by the American Academy of Head and Neck Surgery,World Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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and which is also endorsed by American Society of Head
and Neck Surgery, has become accepted widely [7]. The
principles are as follows:
1. RND is the standard basic procedure for cervical lym-
phadenectomy, and all other procedures represent one or
more modifications of this procedure.
2. When the modification involves preservation of one or
more non-lymphatic structures, the procedure is termed a
modified RND (MRND)
3. When the modification involves removal of additional
nodal groups or non-lymphatic structures relative to
RND, the procedure is termed extended RND.
Table 1: Cervical nodal levels
Levels Nodes Boundaries
Superior Inferior Anterior (medial) Posterior (lateral)
IA Submental 
group
Submental nodes Symphysis of mandible Body of hyoid Anterior belly of 
contralateral digastric 
muscle
Anterior belly of 
ipsilateral digastric 
muscle
IB Submandibular 
group
Submandibular nodes Body of mandible Posterior belly of 
digastric muscle
Anterior belly of 
digastric muscle
Stylohyoid muscle
IIA Upper Jugular 
group Nodes
Nodes around upper 
portions of Internal 
jugular vein and 
Accessory Nerve
Skull base Horizontal plane 
defined by the inferior 
border of hyoid bone
Stylohyoid muscle Vertical plane defined 
by the spinal 
accessory nerve
IIB Upper Jugular 
group Nodes
Skull base Horizontal plane 
defined by the inferior 
border of hyoid bone
Vertical plane defined 
by the spinal 
accessory nerve
Lateral border of the 
sternocleidomastoid 
muscle
III Mid Jugular 
group
Nodes around mid 
portions of Internal 
jugular vein
Horizontal plane 
defined by the inferior 
border of hyoid bone
Horizontal plane 
defined by the inferior 
border of cricoid 
cartilage
Lateral border of the 
sternohyoid muscle
Lateral border of the 
sternocleidomastoid 
muscle or sensory 
branches of the 
cervical plexus
IV Lower Jugular 
group
Nodes around lower 
third of IJV
Horizontal plane 
defined by the inferior 
border of cricoid 
cartilage
Clavicle Lateral border of the 
sternohyoid muscle
Lateral border of the 
sternocleidomastoid 
muscle or sensory 
branches of the 
cervical plexus
VA Posterior 
triangle group
Nodes around lower 
part of Accessory 
nerve and transverse 
cervical vessels
Apex of the 
convergence of 
sternocleidomastoid 
and trapezius muscles
Horizontal plane 
defined by the inferior 
border of cricoid 
cartilage
Lateral border of the 
sternocleidomastoid 
muscle or sensory 
branches of the 
cervical plexus
Anterior border of 
the trapezius muscle
VB Posterior 
triangle group
Horizontal plane 
defined by the inferior 
border of cricoid 
cartilage
Clavicle Lateral border of the 
sternocleidomastoid 
muscle or sensory 
branches of the 
cervical plexus
Anterior border of 
the trapezius muscle
VI Central or 
anterior group
Nodes surrounding 
midline visceral 
structures of neck
Hyoid bone Suprasternal Common carotid 
artery
Common carotid 
artery
Table 2: Regional lymph node staging
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but less than 6 cm in greatest dimension
N2b Metastasis in a multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3 Metastasis in a lymph node more than 6 cm in greatest dimension (Midline nodes are considered ipsilateral nodes)
(Adapted from UICC / AJCC TNM Classification of Malignant Tumors, 6th edition, 2002)World Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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4. When the modification involves preservation of one or
more lymph node groups that are routinely removed in
RND, the procedure is termed as selective neck dissection
(SND).
The first three procedures are also grouped together under
the name of "comprehensive neck dissections". A modi-
fied classification is outlined in Table 4. An example of
extended neck dissection includes removal of parapharyn-
geal or buccinator or superior mediastinal nodes. It could
also involve removal of non-lymphatic structures such as
the hypoglossal or vagus nerves, paraspinal muscles or
carotid artery.
Other terminologies used are "elective" and "therapeutic"
neck dissections. If a neck dissection is carried out when
there is no evidence of neck disease it is termed an "elec-
tive" neck dissection (END). Some authors use the word
"prophylactic" instead of "elective" to denote the same
procedure. However, the word "prophylactic" is not rec-
ommended as it gives a false impression. If the neck dis-
section is undertaken for metastatic disease in the neck it
is called a "therapeutic" neck dissection. An END is usu-
ally, but not always, a SND. Hence END and SND are not
synonymous terms
Management of positive neck nodes
Palpable cervical nodes in patients with carcinoma of the
upper aero-digestive tract are usually assumed to be due to
metastases. Further evaluation with FNAC is needed only
in patients where the nodes do not appear to be due to
metastatic diseases as assessed clinically. At the other
extreme, computerized tomography (CT) scan or mag-
netic resonance imaging (MRI) or a Doppler study may be
required depending on what vital structure appears to be
involved by nodal disease, or when there is a doubt about
the ability to surgically remove the disease.
The presence of nodal metastases reduces survival by 50%
[12,13]. The prognosis of patients with cervical metastases
is affected by the number of metastases, level of metas-
tases, tumor burden, presence of extra capsular spread,
nodal resectability and previous treatment with surgery or
irradiation [12]. With the exception of patients with
nasopharyngeal carcinomas, clinically apparent cervical
Table 3: Patterns of neck nodal metastasis
Primary site First echelon nodes
Oral cavity Levels I, II, III
Larynx, Pharynx Levels II, III, IV
Thyroid Levels IV, VI, superior mediastinal
Parotid Levels II, III, Pre-auricular, Peri & intra 
parotid, Upper accessory chain
Submandibular, sublingual 
glands
Level I, II, III
Diagrammatic representation of the neck showing various  nodal levels and sublevels Figure 1
Diagrammatic representation of the neck showing various 
nodal levels and sublevels
Table 4: Classification of neck dissections*
Comprehensive neck 
dissection
Radical Neck Dissection
Extended Radical Neck Dissection
Modified Radical Neck Dissection type I
Modified Radical Neck Dissection type II
Modified Radical Neck Dissection type III
Selective neck dissection Supraomohyoid neck dissection
Jugular (antero-lateral) neck dissection
Central compartment (anterior) neck 
dissection
Posterolateral neck dissection
*The nomenclature of various selective neck dissections are not 
recommended for usage. They are replaced with SND followed by the 
nodal levels or sublevels removed. However these named procedures 
are retained here as this is a transition phase and this nomenclature 
was being followed not very long ago.World Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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lymph node metastases should be treated with a neck dis-
section [14].
A classical RND has been regarded as the gold standard for
surgical treatment of clinically apparent metastatic cervi-
cal lymph node disease. When regional metastases are
clinically palpable, comprehensive clearance of all the
regional nodes which are at risk is mandatory. The under-
lying principle is that once metastases have occurred to
one node, than there is likely to be sub-clinical metastases
in other nodes. However, the operation has a significant
morbidity which includes shoulder syndrome (shoulder
weakness, deformity, pain, and adhesive capsulitis),
anesthesia over the cutaneous distribution of the cervical
plexus, and cosmetic deformity due to loss of the sterno-
cleidomastoid muscle. The procedure involves removal of
all ipsilateral cervical lymph node groups extending from
the body of the mandible superiorly, to the clavicle inferi-
orly, anteriorly from the lateral border of sternohyoid,
hyoid, contralateral anterior belly of digastric muscle
belly, to the anterior border of trapezius posteriorly.
Nodal groups from level I through to V are included in
this dissection. Important extra-nodal structures such as
the spinal accessory nerve, internal jugular vein and ster-
nocleidomastoid muscle are sacrificed. Post- auricular,
periparotid, suboccipital, perifacial, buccinator, retropha-
ryngeal and paratracheal nodes are not removed in this
nodal dissection.
The current indications for classical RND [15] are:
• N3 neck disease, especially in the upper neck
• Bulky metastatic disease near the accessory nerve
• Tumor directly involving the accessory nerve
• Clinically palpable multiple nodes, especially if near the
accessory nerve (N2b, N2c)
• Recurrent metastatic tumor after previous irradiation
therapy
• Recurrent disease in the neck after previous neck
dissection
• Salvage surgery in patients after chemo-irradiation ther-
apy, especially in those who presented with bulky or level
II nodal disease
• Involvement of the platysma or skin, requiring sacrifice
of a portion of skin in the upper neck
• Clinical or radiological signs of obvious extra-nodal dis-
ease e.g. fixity
On the other hand, when appropriate indications exist, a
function-preserving comprehensive neck dissection,
sparing one or more vital structures, should be considered
as long as it does not compromise the performance of a
satisfactory clearance of metastatic disease. Preservation
of the accessory nerve alone significantly reduces the mor-
bidity of neck dissection. Thus, if the spinal accessory
nerve is not involved by metastatic disease, it should be
routinely preserved even in patients with clinically palpa-
ble metastatic nodes as the accessory nerve is rarely
invaded by metastatic disease, and its preservation does
not affect local recurrence of disease or overall patient sur-
vival. The cervical plexus contributes in part to the motor
supply of trapezius through the accessory nerve [16-18].
However, it has also been pointed out that such a contri-
bution may be insignificant and inconsistent [19]. Spinal
accessory nerve dysfunction occurs even after selective dis-
section and is usually attributed to stretching of the nerve
due to retraction during clearance of level IIb lymph
nodes and/or ischemia [20,21]. Recent anatomical find-
ings have shown that, functionally, the most important
descending part of the trapezius muscle is innervated by a
fine single branch arising from the spinal accessory nerve
in the posterior triangle of the neck. Preservation of this
branch may help to prevent more morbidity in patients
undergoing modified radical neck dissections [22]. Acces-
sory nerve sparing should not result in less than optimum
nodal disease clearance and the nerve should be sacrificed
if warranted in order to achieve this. Preservation of the
sternocleidomastoid muscle, or internal jugular vein, is
not recommended in patients with palpable nodes from
an upper aero-digestive tract primary tumor. However, the
same can be preserved, in addition to the accessory nerve,
in nodal metastases from a well differentiated thyroid car-
cinoma. In addition, the sternomastoid can be preserved
for cosmesis in young individuals and in those with min-
imal nodal disease. When bilateral neck dissection is
undertaken simultaneously, it is important to preserve at
least one internal jugular vein, preferably on the less
involved side. It has also been realized that neck dissec-
tion is inadequate when employed as a sole modality in
disease with adverse histological features such as
perineural invasion and extracapsular spread. This has led
to the usage of combination therapy of surgery with irra-
diation in selected patients. The common indications for
RND, MRND and structures removed or spared are listed
in Table 5. The overall results comparing RND and MRND
[10,23-31] irrespective of the primary tumor are listed in
Table 6. From the above discussion it is apparent that spi-
nal accessory nerve preservation lessens the morbidity to
a great extent and preservation of sternocleidomastoid
muscle and internal jugular vein is of lesser importance.
However, this issue becomes of significance where bilat-
eral neck dissections are required.World Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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The outlook for patients with "fixed" nodes is poor
[12,32]. The poor prognosis is probably due to an incom-
plete resection and there being extracapsular spread of dis-
ease. The term "fixed node" is vague in the sense it conveys
different meaning to different people unless it is known to
what structure is the node "fixed". True fixation occurs in
23 to 50% of patients [32]. Tumors fixed to mandible, lar-
ynx, sternocleidomastoid, prevertebral muscles and mas-
toid process can be resected with a margin of normal
tissue. Invasion of skin can similarly be addressed by a
wide margin of resection with resurfacing then carried
out. Adjuvant irradiation can then be employed for micro-
scopic disease. However, the 5-year survivals are poor and
are reported to be around 15% [32]. Irradiation followed
by salvage surgery did not improve survival and the con-
cept of preoperative irradiation 'to make an inoperable
tumor' "operable" is questionable [32]. Invasion of the
carotid sheath does not preclude surgery and can be
present in 5% of patients [32,33]. Carotid artery invasion
is also associated with a poor prognosis. When the exter-
nal carotid artery alone is involved, it can be sacrificed.
When the common or internal carotid is involved, the
options are either no treatment, debulking with adjuvant
therapy, mixed beam therapy or resection with or without
revascularization. Patients should undergo cerebral blood
flow studies prior to surgery and elective carotid artery
resection can be undertaken. Earlier, carotid resection car-
ried a mortality of 12% and hemiplegia rate of 33% [34].
Recently 22% 2 year disease-free survivals, with acceptable
morbidity, have been described [35]. A median disease-
specific survival of 12 months, with 24% of patients dying
from distant metastases has been reported. The high-risk
of complications, loss of quality of life and mortality,
must be balanced against the natural history of the disease
if it is left untreated [36]. When cervical spine or brachial
plexus is involved, sacrifice of these with their attendant
morbidities should be weighed against the local control of
disease that could be achieved and the benefits that it will
offer to patients.
Bilateral neck disease at initial presentation is a bad prog-
nostic sign with a 5-year survival of only 5% then being
likely [13]. Survival is not affected by laterality but by
nodes larger than 6 cm in size [37]. Therefore, the pres-
ence of bilateral mobile nodes should not preclude treat-
ment. At least one internal jugular vein should be
preserved or reconstructed with a saphenous graft [38] or
polytetrafluoroethelyene graft. Simultaneous ligation of
both internal jugular veins can cause venous congestion,
edema of the head and neck, raised intracranial pressure
and the syndrome of inappropriate secretion of anti-diu-
retic hormone. Salvage surgery following a previous neck
dissection also carries a dismal outlook, with a long-term
survival of less than 5% [39].
Table 5: Comprehensive neck dissection*
Neck dissection Indication Comments
RND Clinically metastatic neck nodes of upper aero-
digestive tract
Sternocleidomastoid, accessory nerve, Internal Jugular 
vein and submandibular gland removed
MRND TYPE I As above, when accessory nerve away from nodal 
disease
Accessory nerve spared. Rest as RND
MRND TYPE II Thyroid well differentiated cancer, nodes selectively 
involving IJV
Sternocleidomastoid, accessory nerve spared. Internal 
Jugular vein sacrificed. Rest as RND
MRND TYPE III Thyroid well differentiated cancer Sternocleidomastoid, accessory nerve, Internal Jugular 
vein spared
EXTENDED RND Extensive involvement of nodes beyond usual levels or 
involvement of contiguous organs
Additional lymph nodes** or other non lymphatic 
structures removed
IJV: internal jugular vein; RND: radical neck dissection
* All procedures involve removal of nodes from level I through V
** Nodal areas include retropharyngeal, parapharyngeal, mediastinal or axillary, Structures include cranial nerves, carotid artery, muscles, skin etc.
Note: It is recommended to uniformly use the term modified radical neck dissection (MRND) and not classify as I or II or III but instead name the 
structures preserved.
Table 6: Overall results (irrespective of site of primary tumor)
Nodal status Neck dissection Neck failure
N+ RND 10% – 22%
MRND type I 4.8% – 26%
N1 RND 8% – 15%
MRND type I 0 – 16%
N2 RND 12% – 26%
MRND type I 15% – 25%
N3 RND 21%
RND: radical neck dissection; MRND: modified radical neck 
dissectionWorld Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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As an extension of conservation surgery, some authorities
advocate SND for metastatic neck nodes [40,41]. These
have been only applied in cases without evidence of mas-
sive lymphadenopathy, node fixation or gross extra-cap-
sular spread. In addition, when a suspicious node is
encountered in the lower limit of the dissection, a formal
RND or its modifications can be undertaken. Although
the primary site in these cases varies, it has been report-
edly performed in low grade buccal or buccoalveolar
lesions by an experienced surgeon. SND, when used in
combination with postoperative irradiation therapy, has
been shown to achieve comparable results to those
reported for RND [42]. However, as a routine, a SND is
not recommended for patients whose neck nodes are pos-
itive for tumor.
The role of neck dissection after definitive chemoradio-
therapy for squamous cell head and neck cancer is not
clearly defined [43]. After chemoradiotherapy (5 Fluorou-
racil and cisplatin), clinical parameters do not identify
those patients with residual neck node disease or those at
risk for regional failure, suggesting that neck dissection
should be considered for all patients with N2-N3 disease
[43]. A retrospective non- randomized study showed that
the 5-year survival rate was significantly higher for those
who had postoperative radiotherapy (38.9%) compared
with patients who had pre-operative radiotherapy (9.1%)
and those having surgery alone (0%). They were unable to
evaluate the role of definitive chemotherapy and/or radi-
otherapy and salvage surgery as the results were inconsist-
ent and the available data was limited [44].
Surgical resection is an essential component of aggressive
chemoradiation protocols to ensure tumor control at the
primary site and also in the neck. Neck dissections in
patients with initial node positive disease reveal residual
nodal metastases in 22% [45]. A German multicenter ran-
domized trial showed that accelerated chemoradiation
(Mitomycin and 5 Fluorouracil) to 70.6 Gy was more
effective than accelerated radiation to 77.6 Gy alone.
Selective lymph node dissection of residual neck masses
after completion of hyperfractionated accelerated radio-
(chemo-)therapy is likely to contribute to loco-regional
tumor control in patients with advanced head and neck
cancers [46]. On the contrary, another study did not rec-
ommend neck dissection for patients who respond com-
pletely after chemoradiation but did recommend it for
patients with either no or partial radiographic responses
[47]. Another study showed improved neck control with
neck dissection for patients with clinically residual disease
or N3 neck cancer but no significant impact on the out-
come of patients with N2 stage disease who were rendered
clinically disease-free with intensive concurrent chemora-
diation [48]. There is also a suggestion that neck dissec-
tion followed by chemoradiotherapy has a higher, and
statistically significant, disease-specific survival rate com-
pared to chemoradiation alone [49]. Consensus regarding
the use of neck dissections for complete responders and
incomplete responders has yet to be achieved and the data
are controversial. A possible benefit from neck dissection
after a complete response of the primary tumor after com-
bined chemoradiation or definitive external radiation for
advanced squamous cell carcinoma of the head and neck
may only be anticipated in patients with persisting sub-
clinical neck disease who have no other sites of disease.
Some clinicians have even argued that the salvage rate for
clinically detectable residual neck disease does not justify
neck dissection being performed. Randomized trials
addressing these questions, and a trial addressing the
accuracy of new imaging modalities such as post chemo-
therapy and post radiation positron emission tomogra-
phy scanning, across multiple institutions would be
appropriate [50,51].
Pathological evaluation of the neck dissection specimens
is important. A RND or MRND specimen should comprise
of at least 10 nodes on pathological examination. Apart
from the number of involved nodes it is important to
identify adverse prognostic factors resulting in a predispo-
sition to local recurrence and a reduced survival.
Perineural invasion, extracapsular spread and vascular
invasion indicate a bad prognosis [52,53]. Desmoplastic
stromal reaction was associated with a seven fold increase
in the risk of recurrent disease. Tumor has been identified
up to 12 cm along the perineural space in patients with
perineural invasion, and should be considered as a posi-
tive tumor margin [2]. Patients with poor prognostic
factors listed above should receive adjuvant therapy such
as irradiation, with or without chemotherapy, as required.
Management of patients with N0 neck status
As discussed earlier, comprehensive neck dissection is the
standard treatment for obvious nodal disease in the neck.
With emphasis on function preservation and cosmesis in
addition to achieving adequate local disease control, con-
servative neck dissections have gained popularity. Grow-
ing historical evidence suggests that modified and
selective neck dissections offer disease control compara-
ble to radical neck dissection but with less morbidity
[6,40,54,55].
The problem
It is well known that 20% to 40% of patients with head
and neck cancer who have no palpable disease in their
necks will harbor occult disease in their necks. It is, there-
fore, therapeutically tempting to treat the neck in these
patients on the basis that this will avoid subsequent treat-
ment, which may be not as effective. It means that 60%-
80% of patients are "over-treated". The pros and cons of
this [56-61] are addressed in Table 7.World Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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Evaluation of patients with N0 neck status
Cervical nodal staging is a major challenge. Clinical exam-
ination is influenced by the skill of the examiner, the
patient's body habitus and whether the patient has had
previous surgical or irradiation therapy. As a result of
these factors, the false negative rate in clinical assessment
ranges from 20%-51% [62]. Imaging techniques such as
CT scanning, MRI and ultrasound have been used for eval-
uation. The sensitivity of CT scanning is 81% [63]. Size of
nodes and central lucency of nodes have been used as cri-
teria for identifying nodes containing metastatic tumor
but there is a low specificity [64]. Routine scanning of the
neck in a patient with a head and neck primary tumor is
not justifiable at present. With ultrasound and ultrasound
guided aspiration, the accuracy has improved to 89% but
it is highly operator- dependent [65]. No pre-treatment
study can accurately assess or replace the requirement to
stage the neck histopathologically [63]. Hence the goal of
identifying 'sub-clinical disease' without surgical interven-
tion remains elusive.
Surgical management
A standard RND has no role in the management of
patients with N0 neck status. A SND, or rarely a MRND,
would be required. A recent study has shown comparable
recurrence rates for RND compared with SND with there
being no statistically significant difference [66]. It has to
be emphasized that an END procedure must be "individ-
ualized". The decision regarding the type of neck dissec-
tion depends on the site of primary tumor, other tumor
factors (e.g. location, depth, size, differentiation, vascular
or perineural invasion), the patient and the surgeon
undertaking the procedure. Tumors of the tongue, floor of
mouth, nasopharynx, oropharynx, hypopharynx and sup-
raglotic larynx have a high incidence of nodal metastases.
In contrast, tumors of the buccal mucosa, lip, paranasal
sinuses and glottic larynx metastasize less frequently. For
a patient who stays some distance from the surgical centre
and who is not expected to come for regular follow-up
(and for unreliable patients) an END would be a better
option. Documentation of differences in regional control
rates or survival between patients undergoing END for N0
disease or patients undergoing therapeutic neck dissection
for N1 disease remains controversial. Some authors claim
no difference [10] while other studies have shown that
END significantly improved regional control of the dis-
ease [67,68]. Unfortunately, many patients do not present
later with just N1 disease but with disease greater than
that of N1 staging [10]. Hence END must always be
considered based on the primary tumor characteristics as
prognosis depends on the extent of metastatic neck nodal
disease. An END accurately stages the disease pathologi-
cally, detects and treats micro-metastases, thus controlling
regional disease and helping in the planning of adjuvant
therapy.
When level IV nodes are removed along with supraomo-
hyoid neck dissection (SOND), as in primary tongue, ter-
minologies like extended SOND have been used. This
adds to the complexity of the classification. Further, the
classification of types of SND does not have nomenclature
options if the surgeon preserves certain nodal sublevels.
Hence, it is recommended to use the nodal levels or sub-
levels which are dissected instead of the named SND [8].
Radiation in patients with N0 neck status
External radiation in doses of 40 to 50 Gy will control
occult metastases in 90 to 95% of cases [69]. Although
prospective evidence is lacking, retrospective data suggest
that for most sites and for early lesions, elective nodal irra-
diation (ENI) and END offers equivalent local control
[54,70]. Proponents of ENI assert that the morbidity is
low with limited soft tissue changes and does not have
systemic ramifications. However, considerable acute
adverse effects such as mucositis and xerostomia, together
with late effects like endarteritis, radionecrosis etc .can
occur. Systemic effects include suppression of humoral
and cell mediated immunity.
Table 7: Pros and cons for elective neck dissection (END)
For END Against END
Neck dissection has low morbidity & mortality END results in a large number of unnecessary surgical procedures and is 
associated with inevitable morbidity
Cure rate for neck dissection is decreased if gland enlargement occurs 
or multiple nodes appear
Cure rates are no lower if the surgeon waits for the neck to convert 
from N0 to N1
It is impossible to provide follow-up necessary to detect the earlier 
conversion of a neck from N0 to N1
Careful clinical follow-up will allow detection of the earliest conversion 
from N0 to N1
Allowing the neck metastases to develop increases the incidence of 
distant metastasis
END removes the barrier to the spread of disease and also has a 
detrimental immunological effect
If neck has been entered to remove the primary it is better to perform 
an in-continuity resection
Radiation is as effective as neck dissection in N0 neck
High incidence of occult metastatic diseaseWorld Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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The issue of the use of elective surgery versus elective radi-
ation ends not at which treatment modality is more ben-
eficial, but which one is less harmful. The patient's age,
general health, family support, reliability and patient's
own wishes are important. It is impossible to compare
elective neck dissection and elective nodal irradiation effi-
cacy because the status of neck disease is unknown when
elective irradiation is used. The accurate histological infor-
mation on micrometastases in neck nodes in patients with
clinically negative neck nodes is probably one of the
prime factors that tilts the argument towards nodal dissec-
tion, apart from the lesser associated morbidity. If the
treatment planning for the primary tumor involves surgi-
cal excision through a neck approach, END is opted for
when indicated. If the primary tumor is being treated with
irradiation, an elective irradiation of nodal area should be
planned.
Most authors recommend that END be performed when
the expected incidence of microscopic or subclinical dis-
ease exceeds 20%. The National Cancer Comprehensive
Network's adopted practice guidelines recommend END
for cancers of the oral cavity, oropharynx, hypopharynx
and supraglottic larynx when the nodal status is N0.
Tumors of the nasopharynx are primarily treated with
radiotherapy, which includes nodal management. Surgery
plays a limited role with this being restricted to salvage of
residual neck disease following failure of primary
radiotherapy.
For oral tumors, the high incidence of occult nodal metas-
tases, and notoriously poor salvage rates, make expectant
treatment ill-advised in most cases [54,55,71]. The lower
alveolar ridge carcinomas have a low potential for neck
metastases [72]. With the exception of this, treatment of
sub-clinical neck disease is indicated for all oral cavity
lesions. It is also important to note that carcinomas of the
oral cavity rarely spread to lower jugular or posterior cer-
vical nodes in the absence of involvement of level I-III. An
elective SND (levels I – III) provides staging information
and may be the only therapy necessary for occult disease.
It has minimal morbidity and it reduces the risk of occult
disease evolving into clinically evident metastases. In
addition, the undesirable effects of radiotherapy are
avoided. A tongue tumor with a depth of invasion of more
than 4 mm is likely to produce occult nodal metastases
[73]. As a sub-site of oral tumors, the tongue is notorious
for nodal metastases. For a well differentiated T1 tumor,
with less than 4 mm of muscle invasion and a clinical N0
status in the neck, a model predicts a 14% chance of nodal
metastases. Sub-digastric and mid jugular are the most fre-
quently involved nodal groups in primary oral cavity
tumors [65]. Evidence also indicates that level IV nodes
may also be at risk in a tongue primary cancer [74]. An
ipsilateral SND (levels I – IV) is indicated for tongue pri-
maries. Both sides of the neck have to be addressed in
midline, or near the midline, tongue primaries.
In tumors of the oropharynx, the risk of occult nodal
metastases is 30%-35%. There is a high incidence of level
II, III and IV involvement [55,74]. In addition, there is an
increased risk of bilateral occult nodal disease in tumors
near the midline and treatment should include both sides
of the neck. Tumors of the hypopharynx are known for
extensive sub-mucosal spread. The retropharyngeal and
paratracheal nodes are also at risk of harboring metas-
tases. Occult nodal metastases are present in approxi-
mately 30%-55% of patients with primary
hypopharyngeal tumors and occur frequently in the con-
tralateral side of the neck [55,75]. As stated earlier, the
modality used in the treatment of the primary is an impor-
tant consideration whilst planning treatment of the neck.
Larger tumors (T3 or greater) usually require combined
therapy. In cases where surgery is chosen to treat an
advanced primary cancer, a bilateral neck dissection aim-
ing at removal of all the nodes at risk is performed. If com-
bined therapy is planned, a unilateral neck dissection is
undertaken and irradiation may be used to treat the un-
dissected neck. The choice of treatment is dependent on
various factors as discussed earlier.
In tumors of the supraglottic larynx, the location of the
tumor has a prognostic significance. Marginal lesions like
those on aryepiglottic fold and suprahyoid margin of the
epiglottis behave more aggressively with an increased risk
of nodal metastases. There is also a high risk of contralat-
eral nodal metastasis for lateral (aryepiglottic fold) as well
as midline (epiglottic) lesions. This makes bilateral neck
dissections a necessity when electively performed [76].
Carcinoma of the supraglottic larynx has a high incidence
of occult metastases in the range of around 30% [55].
Based on current evidence, if surgery is planned for
primary therapy, SND of levels II through IV is acceptable
[77]. Dissections need to be bilateral to prevent contralat-
eral neck failure and recurrence of disease. As stated
earlier, if irradiation is planned, the contralateral side of
the neck may be irradiated.
In contrast, glottic cancers remain localized due to sparse
lymphatics. T1 and T2 carcinomas have less than 7%
nodal metastases. If such patients are available for regular
follow-up, these patients may be closely observed. But,
recurrent cancers have a significantly higher occult metas-
tases rate reaching 20%-22%. An END incorporating lev-
els II through IV may be planned [55,77]. T3 and T4
glottic carcinomas have occult nodal metastasis in the
range of 20%-40%. In addition, salvage rates for recur-
rences are dismal. Hence, T3 and T4 glottic carcinomasWorld Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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should receive ipsilateral SND of levels II through IV and
level VI.
The reported incidence of subglottic tumors is low. These
have a high incidence of extralaryngeal spread due to the
proximity of the cricothryoid membrane and the rich
post-cricoid lymphatics. They drain to pre- and para-tra-
cheal, pre-laryngeal and superior mediastinal nodes. The
sparse data makes conclusive recommendations difficult.
However, a wide field laryngectomy, bilateral para-tra-
cheal dissection, pre-laryngeal nodal dissection with an
ipsilateral hemithyroidectomy should be planned with
postoperative radiation to stoma, mediastinum and both
sides of neck. An organ based general plan of SND is out-
lined in Table 8.
A SND should include at least 6 nodes on pathological
examination. If nodes appear involved near the lower end
of the dissection, the SND should be converted to a for-
mal MRND. Alternatively, if facilities are available, frozen
section can be employed.
SND is traditionally looked upon as a diagnostic or stag-
ing procedure. Increasing evidence indicates that the pro-
cedure could definitely be therapeutic, at least in N0 and
early N+ disease, with results comparable to RND [40].
The therapeutic efficacy of SND is not diminished in the
presence of occult nodal disease. However, other evidence
indicates that recurrence rates are higher if post-operative
irradiation is not used when one or more nodes are path-
ologically positive after SND [78]. SND followed by irra-
diation if nodal metastases are detected by pathology later
is one area under investigation.
Trends in management of patients with N0 neck status
Sentinel node biopsy (SNB) This new concept is an in vivo
assessment of tumoral spread to lymph nodes and could
be useful in patients with N0 neck status where the prob-
lem is whether to treat, or wait and watch. The procedure
is similar to that followed for SNB in patients with breast
cancer or melanoma, the drawbacks are also similar. The
SNB is performed after radiocolloid and blue dye injec-
tion (either alone or in combination). Preoperative lym-
phoscintigraphy and peri-operative use of a gamma probe
identifies radioactive sentinel nodes and visualization of
blue stained lymphatics and identify the blue sentinel
node(s). No further nodal dissection is done if the SNB is
negative, whilst therapeutic neck dissection is performed
when the SNB is found to harbor malignancy. Various
studies have illustrated the feasibility of the procedure in
patients with head and neck cancers [79,80]. The sensitiv-
ity of the procedure is reported to be 94%. The argument
for undertaking such a procedure is that it does not result
in an excessive form of treatment whilst at the same time
it does not neglect the oncological safety aspects.
A suggestion has been made to divide the occult metas-
tases seen on microscopy in these nodes into isolated
tumoral cells, micrometastases and macrometastases. Pre-
liminary results of one trial shows that SNB is of value in
patients with T1 and T2 tumors of the oral cavity and
oropharynx [81]. Although the procedure holds promise
for the future, more randomized studies and long-term
follow-up are needed before this procedure is accepted as
the standard of care [81-84]. Unresolved issues include
identification of patient and tumor characteristics
appropriate for this methodology, for example, stage, site
or subsite [85]. Another important issue which has to be
addressed is whether immunohistochemical or molecular
studies are required on SNB and the clinical implication
of such micrometastases.
Endoscopic neck dissections
With the advent of minimally invasive surgery, and after
its success in certain abdominal conditions, the same has
been tried in other areas of cancer management. Early
Table 8: Selective neck dissection (N0 neck)
Organ Nodal clearance
Oral cavity I, II, III
Tongue I, II, III, !V
Hypopharynx, larynx, oropharynx II, III, IV
Some laryngeal and hypopharyngeal lesions where IIB is not removed IIA, III, IV
Laryngeal, hypopharyngeal extending below glottis II, III, IV, VI
Thyroid, hypopharynx, cervical trachea, cervical esophagus, sub-glottic 
larynx
VI,
Cutaneous carcinoma of posterior scalp and upper neck II – V, Post auricular, Suboccipital
Cutaneous malignancy from pre-auricular, anterior scalp and temporal 
region
II, III, VA, parotid, facial, external jugular nodes
Cutaneous malignancy of anterior or lateral face I, II, IIIWorld Journal of Surgical Oncology 2005, 3:21 http://www.wjso.com/content/3/1/21
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experiments on animals and cadavers have been fairly suc-
cessful [86]. Although the feasibility of the procedure has
been shown, it's oncological safety and useful in practice
are other issues that need to be addressed. The questions
to be answered include whether such a procedure benefits
the patient to the extent other endoscopic procedures
have [87]. It remains to be seen if the procedure gains
widespread acceptance in clinical practice.
Positron emission tomography (PET) and single photon emission 
computed tomography (SPECT)
PET may be able to detect nodal metastases in nodes that
are judged to be negative by size criteria. SPECT imaging
with deoxy-18F-fluoro-D-glucose or thallium is able to
detect nodal disease. SPECT using Tc-99 m labeled mono-
clonal antibodies can visualize most lymph node metas-
tases. However, the accuracy is superior when combined
with CT scanning [87]. PET is at present prohibitively
expensive but in future it may have a role in detecting
occult nodal disease. Further studies are required to corre-
late the scan results with histological results of node
examinations.
Conclusion
Neck dissection is the standard therapy for patients with
metastatic neck nodes. RND has now been replaced with
MRND for selected cases of patients with node positive
neck disease. The improvements in understanding the
biology of cancer and techniques in surgery have led to
this change with its associated reduction in morbidity.
Imaging studies to predict histological nodal metastases
have so far not been successful. Evaluation is underway to
replace MRND with SND for early nodal disease. SNB may
replace SND for patients with N0 disease in future but cer-
tain issues still need to be addressed. Finally, whether
endoscopic neck dissections will replace the existing pro-
cedures remains to be evaluated.
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